PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 115 | +8 | 58.79M | $4.78B | +13 | −5 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | — |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | — |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | — |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | — | — |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | — | −2 |
| Q2 2024 | 13 | — | 14.28M | $436.54M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasivo) | 1.79M | — | $54.68M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (pasivo) | 1.79M | — | $54.68M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 1.36M | — | $41.52M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 1.36M | — | $41.52M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 1.36M | — | $41.52M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 818.10K | — | $25.02M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 606.68K | — | $18.55M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 606.68K | — | $18.55M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 318.17K | — | $9.73M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Millennium Management ✦ | 317.58K | — | $9.71M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 300.00K | — | $9.17M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 270.08K | — | $8.26M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 270.08K | — | $8.26M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Marshall Wace ✦ | 179.68K | — | $5.49M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 179.68K | — | $5.49M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 68.91K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 68.91K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 68.91K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Point72 Asset Management ✦ | 26.70K | — | $816,486 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Norges Bank ✦ (pasivo) | 15.10K | — | $461,758 | 0.0% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 4.16M acciones, $5.53M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 2.39K acc. · $171,793
Director · 691 acc. · $50,388
Director · 9.42K acc. · $666,677
Director · 7.17K acc. · $527,846
Director · 5.33K acc. · $388,708
Officer · 969 acc. · $70,640
Officer · 1.84K acc. · $133,487
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología